Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended September 30, 2006. The registrant is a foreign private issuer based in South Melbourne, Australia, reporting under Rule 13a-16. The document serves as a quarterly report for entities admitted on the basis of commitments, detailing cash flow activities and compliance with Australian accounting standards.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Receipts from Customers | 0 |
| Net Operating Cash Flows | (2,691) |
| Net Investing Cash Flows | 0 |
| Net Financing Cash Flows | 43 |
| Net Decrease in Cash | (2,648) |
| Cash at Beginning of Quarter | 10,014 |
| Cash at End of Quarter | 7,218 |
| Research and Development Payments | (1,785) |
| Staff Costs Payments | (488) |
| Payments to Directors/Associates | 170 |
The filing does not provide a clear value for revenue, profit, margins, or total debt, as the report focuses exclusively on cash flow movements rather than accrual-based income statements or balance sheet totals.
Material Changes and Activities
- Operating Burn: The company reported no receipts from customers, resulting in a net operating cash outflow of $2.691 million. The primary cash outflows were for research and development ($1.785 million) and staff costs ($488 thousand).
- Financing Activity: The company raised $43 thousand through proceeds from the issue of shares or options. There were no borrowings or repayments of borrowings.
- Liquidity Position: Cash reserves decreased by approximately 26% during the quarter, dropping from $10.014 million to $7.218 million. This decrease includes a $148 thousand reduction due to exchange rate adjustments.
- Investing Activity: There were no cash flows related to the acquisition or disposal of businesses, equity investments, or physical assets.
Guidance, Risks, and Contingencies
The filing does not contain specific management guidance, forward-looking outlook statements, or a detailed discussion of risks and contingencies. The document is a compliance report focused on cash flow transparency. The only noted risk factor is the continued negative operating cash flow in the absence of customer receipts, which is typical for a pre-revenue biotechnology entity.
Investor Verification Checklist
- Verify the company's runway by comparing the current cash balance ($7.218 million) against the quarterly burn rate ($2.691 million).
- Confirm the status of the $1.785 million R&D expenditure to ensure it aligns with expected clinical or development milestones.
- Review the $43 thousand share issuance to understand the dilution impact and whether it was part of a larger capital raise plan.
- Check for any subsequent filings regarding the $148 thousand exchange rate loss to assess currency exposure risks.